<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33780440</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7404</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>PLoS genetics</Title><ISOAbbreviation>PLoS Genet</ISOAbbreviation></Journal><ArticleTitle>Characterization of C9orf72 haplotypes to evaluate the effects of normal and pathological variations on its expression and splicing.</ArticleTitle><Pagination><StartPage>e1009445</StartPage><MedlinePgn>e1009445</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1009445</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgen.1009445</ELocationID><Abstract><AbstractText>Expansion of the hexanucleotide repeat (HR) in the first intron of the C9orf72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) in Caucasians. All C9orf72-ALS/FTD patients share a common risk (R) haplotype. To study C9orf72 expression and splicing from the mutant R allele compared to the complementary normal allele in ALS/FTD patients, we initially created a detailed molecular map of the single nucleotide polymorphism (SNP) signature and the HR length of the various C9orf72 haplotypes in Caucasians. We leveraged this map to determine the allelic origin of transcripts per patient, and decipher the effects of pathological and normal HR lengths on C9orf72 expression and splicing. In C9orf72 ALS patients' cells, the HR expanded allele, compared to non-R allele, was associated with decreased levels of a downstream initiated transcript variant and increased levels of transcripts initiated upstream of the HR. HR expanded R alleles correlated with high levels of unspliced intron 1 and activation of cryptic donor splice sites along intron 1. Retention of intron 1 was associated with sequential intron 2 retention. The SNP signature of C9orf72 haplotypes described here enables allele-specific analysis of transcriptional products and may pave the way to allele-specific therapeutic strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ben-Dor</LastName><ForeName>Israel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-9745-5196</Identifier><AffiliationInfo><Affiliation>The Hadassah Human Embryonic Stem Cell Research Center, The Goldyne Savad Institute of Gene Therapy, Hadassah Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacut</LastName><ForeName>Crystal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nevo</LastName><ForeName>Yuval</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Computation Center, Hebrew University-Hadassah Medical School, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><Identifier Source="ORCID">0000-0002-9162-2694</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reubinoff</LastName><ForeName>Benjamin E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0003-0353-1299</Identifier><AffiliationInfo><Affiliation>The Hadassah Human Embryonic Stem Cell Research Center, The Goldyne Savad Institute of Gene Therapy, Hadassah Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Genet</MedlineTA><NlmUniqueID>101239074</NlmUniqueID><ISSNLinking>1553-7390</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022821">RNA Splice Sites</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="Y">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="Y">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007438" MajorTopicYN="N">Introns</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022821" MajorTopicYN="N">RNA Splice Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="Y">RNA Splicing</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The Authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>29</Day><Hour>17</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33780440</ArticleId><ArticleId IdType="pmc">PMC8031855</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1009445</ArticleId><ArticleId IdType="pii">PGENETICS-D-20-01137</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen PM (2000) Genetic factors in the early diagnosis of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 1 Suppl 1: S31&#x2013;42. 10.1080/14660820052415899</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820052415899</ArticleId><ArticleId IdType="pubmed">11464924</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Grassi M, Bianchi M, Bruni AC, Maletta RG, et al.. (2014) Estimating the inheritance of frontotemporal lobar degeneration in the Italian population. J Alzheimers Dis 41: 371&#x2013;376. 10.3233/JAD-130128</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-130128</ArticleId><ArticleId IdType="pubmed">23719513</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al.. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72: 245&#x2013;256. 10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, et al.. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72: 257&#x2013;268. 10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EG, Waite A, et al.. (2012) Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 11: 323&#x2013;330. 10.1016/S1474-4422(12)70043-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, et al.. (2013) Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet 92: 345&#x2013;353. 10.1016/j.ajhg.2013.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.01.011</ArticleId><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Gijselinck I, Dillen L, Van Langenhove T, Theuns J, et al.. (2013) A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat 34: 363&#x2013;373. 10.1002/humu.22244</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22244</ArticleId><ArticleId IdType="pmc">PMC3638346</ArticleId><ArticleId IdType="pubmed">23111906</ArticleId></ArticleIdList></Reference><Reference><Citation>Gami P, Murray C, Schottlaender L, Bettencourt C, De Pablo Fernandez E, et al.. (2015) A 30-unit hexanucleotide repeat expansion in C9orf72 induces pathological lesions with dipeptide-repeat proteins and RNA foci, but not TDP-43 inclusions and clinical disease. Acta Neuropathol 130: 599&#x2013;601. 10.1007/s00401-015-1473-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1473-5</ArticleId><ArticleId IdType="pubmed">26347457</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Walsh MJ, Higginbottom A, Robin Highley J, Dickman MJ, et al.. (2014) Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain 137: 2040&#x2013;2051. 10.1093/brain/awu120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu120</ArticleId><ArticleId IdType="pmc">PMC4065024</ArticleId><ArticleId IdType="pubmed">24866055</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, et al.. (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77: 639&#x2013;646. 10.1016/j.neuron.2013.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer PO (2016) Methylation of C9orf72 expansion reduces RNA foci formation and dipeptide-repeat proteins expression in cells. Neurosci Lett 612: 204&#x2013;209. 10.1016/j.neulet.2015.12.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2015.12.018</ArticleId><ArticleId IdType="pubmed">26690922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Hadad Y, Altarescu G, Eldar-Geva T, Levi-Lahad E, Zhang M, et al.. (2016) Marked Differences in C9orf72 Methylation Status and Isoform Expression between C9/ALS Human Embryonic and Induced Pluripotent Stem Cells. Stem Cell Reports 7: 927&#x2013;940. 10.1016/j.stemcr.2016.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2016.09.011</ArticleId><ArticleId IdType="pmc">PMC5106522</ArticleId><ArticleId IdType="pubmed">27773700</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Russ J, Wu K, Neal D, Suh E, et al.. (2014) C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathol 128: 525&#x2013;541. 10.1007/s00401-014-1286-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1286-y</ArticleId><ArticleId IdType="pmc">PMC4161616</ArticleId><ArticleId IdType="pubmed">24806409</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zinman L, Moreno D, Schymick J, Liang Y, et al.. (2013) Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet 92: 981&#x2013;989. 10.1016/j.ajhg.2013.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.04.017</ArticleId><ArticleId IdType="pmc">PMC3675239</ArticleId><ArticleId IdType="pubmed">23731538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Rainero I, Rubino E, Pinessi L, Bruni AC, et al.. (2014) Hypermethylation of the CpG-island near the C9orf72 G(4)C(2)-repeat expansion in FTLD patients. Hum Mol Genet 23: 5630&#x2013;5637. 10.1093/hmg/ddu279</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu279</ArticleId><ArticleId IdType="pubmed">24908669</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zhang M, Bruni AC, Maletta RG, Colao R, et al.. (2015) The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathol 129: 715&#x2013;727. 10.1007/s00401-015-1401-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1401-8</ArticleId><ArticleId IdType="pubmed">25716178</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick P, Sellier C, Mackenzie IRA, Cheng CY, Tahraoui-Bories J, et al.. (2018) Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathol Commun 6: 72. 10.1186/s40478-018-0579-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0579-0</ArticleId><ArticleId IdType="pmc">PMC6091050</ArticleId><ArticleId IdType="pubmed">30075745</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite AJ, Baumer D, East S, Neal J, Morris HR, et al.. (2014) Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol Aging 35: 1779 e1775&#x2013;1779 e1713. 10.1016/j.neurobiolaging.2014.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.01.016</ArticleId><ArticleId IdType="pmc">PMC3988882</ArticleId><ArticleId IdType="pubmed">24559645</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao FB, Almeida S, Lopez-Gonzalez R (2017) Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. EMBO J 36: 2931&#x2013;2950. 10.15252/embj.201797568</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797568</ArticleId><ArticleId IdType="pmc">PMC5641681</ArticleId><ArticleId IdType="pubmed">28916614</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Jiang J, Gendron TF, McAlonis-Downes M, Jiang L, et al.. (2020) Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat Neurosci 23: 615&#x2013;624. 10.1038/s41593-020-0619-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0619-5</ArticleId><ArticleId IdType="pmc">PMC7384305</ArticleId><ArticleId IdType="pubmed">32284607</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, ORourke JG, Meera P, Muhammad AK, Grant S, et al.. (2013) Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med 5: 208ra149. 10.1126/scitranslmed.3007529</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007529</ArticleId><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Laaksovirta H, Peuralinna T, Schymick JC, Scholz SW, Lai SL, et al.. (2010) Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol 9: 978&#x2013;985. 10.1016/S1474-4422(10)70184-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70184-8</ArticleId><ArticleId IdType="pmc">PMC2965392</ArticleId><ArticleId IdType="pubmed">20801718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok K, Traynor BJ, Schymick J, Tienari PJ, Laaksovirta H, et al.. (2012) Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol Aging 33: 209 e203&#x2013;208. 10.1016/j.neurobiolaging.2011.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.08.005</ArticleId><ArticleId IdType="pmc">PMC3312749</ArticleId><ArticleId IdType="pubmed">21925771</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno T, Shiga A, Tsujino A, Sugai A, Kato T, et al.. (2013) Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72. J Neurol Neurosurg Psychiatry 84: 398&#x2013;401. 10.1136/jnnp-2012-302272</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-302272</ArticleId><ArticleId IdType="pubmed">23012445</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein O, Gana-Weisz M, Nefussy B, Vainer B, Nayshool O, et al.. (2018) High frequency of C9orf72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis patients from two founder populations sharing the same risk haplotype. Neurobiol Aging 64: 160 e161&#x2013;160 e167. 10.1016/j.neurobiolaging.2017.12.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.12.015</ArticleId><ArticleId IdType="pmc">PMC5931221</ArticleId><ArticleId IdType="pubmed">29352617</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Newhouse S, Shatunov A, Vance C, Topp S, et al.. (2013) The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet 21: 102&#x2013;108. 10.1038/ejhg.2012.98</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2012.98</ArticleId><ArticleId IdType="pmc">PMC3522204</ArticleId><ArticleId IdType="pubmed">22692064</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Yanez A, Lall D, Wolf AJ, et al.. (2016) C9orf72 is required for proper macrophage and microglial function in mice. Science 351: 1324&#x2013;1329. 10.1126/science.aaf1064</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1064</ArticleId><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, Li Y, Chang WH, et al.. (2018) Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med 24: 313&#x2013;325. 10.1038/nm.4490</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4490</ArticleId><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivadasan R, Hornburg D, Drepper C, Frank N, Jablonka S, et al.. (2016) C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons. Nat Neurosci 19: 1610&#x2013;1618. 10.1038/nn.4407</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4407</ArticleId><ArticleId IdType="pubmed">27723745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali CP, Patino M, Tai YK, Ho WY, McLean CA, et al.. (2019) C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathol. 10.1007/s00401-019-02045-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02045-5</ArticleId><ArticleId IdType="pmc">PMC6802287</ArticleId><ArticleId IdType="pubmed">31327044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao P, Wang QJ, Zhu XT, Zhou H, Li R, et al.. (2011) Quantitative determination of allele frequency in pooled DNA by using sequencing method. J Chromatogr B Analyt Technol Biomed Life Sci 879: 527&#x2013;532. 10.1016/j.jchromb.2011.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchromb.2011.01.014</ArticleId><ArticleId IdType="pubmed">21277843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurpeisov V, Hurwitz SJ, Sharma PL (2003) Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase. J Clin Microbiol 41: 3306&#x2013;3311. 10.1128/jcm.41.7.3306-3311.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.41.7.3306-3311.2003</ArticleId><ArticleId IdType="pmc">PMC165373</ArticleId><ArticleId IdType="pubmed">12843079</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, McLeod S, Elfick D, Dekkers JC, Lamont SJ (2006) Rapid identification of single nucleotide polymorphisms and estimation of allele frequencies using sequence traces from DNA pools. Poult Sci 85: 1165&#x2013;1168. 10.1093/ps/85.7.1165</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ps/85.7.1165</ArticleId><ArticleId IdType="pubmed">16830855</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EA, Shaw PG, et al.. (2014) C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 507: 195&#x2013;200. 10.1038/nature13124</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13124</ArticleId><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Sznajder LJ, Thomas JD, Carrell EM, Reid T, McFarland KN, et al.. (2018) Intron retention induced by microsatellite expansions as a disease biomarker. Proc Natl Acad Sci U S A 115: 4234&#x2013;4239. 10.1073/pnas.1716617115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1716617115</ArticleId><ArticleId IdType="pmc">PMC5910826</ArticleId><ArticleId IdType="pubmed">29610297</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H, Almeida S, Moore J, Gendron TF, Chalasani U, et al.. (2015) Differential Toxicity of Nuclear RNA Foci versus Dipeptide Repeat Proteins in a Drosophila Model of C9ORF72 FTD/ALS. Neuron 87: 1207&#x2013;1214. 10.1016/j.neuron.2015.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.09.015</ArticleId><ArticleId IdType="pmc">PMC4589299</ArticleId><ArticleId IdType="pubmed">26402604</ArticleId></ArticleIdList></Reference><Reference><Citation>Birger A, Ben-Dor I, Ottolenghi M, Turetsky T, Gil Y, et al.. (2019) Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity. EBioMedicine 50: 274&#x2013;289. 10.1016/j.ebiom.2019.11.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.11.026</ArticleId><ArticleId IdType="pmc">PMC6921360</ArticleId><ArticleId IdType="pubmed">31787569</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Lin Z, Chen X, Cao B, Wei Q, et al.. (2016) Large C9orf72 repeat expansions are seen in Chinese patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging 38: 217 e215&#x2013;217 e222. 10.1016/j.neurobiolaging.2015.11.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.11.016</ArticleId><ArticleId IdType="pubmed">26725464</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Tang L, Benyamin B, Shah S, Hemani G, et al.. (2015) C9orf72 hexanucleotide repeat expansions in Chinese sporadic amyotrophic lateral sclerosis. Neurobiol Aging 36: 2660 e2661&#x2013;2668. 10.1016/j.neurobiolaging.2015.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.06.002</ArticleId><ArticleId IdType="pubmed">26142124</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamim U, Ambawat S, Singh J, Thomas A, Pradeep-Chandra-Reddy C, et al.. (2020) C9orf72 hexanucleotide repeat expansion in Indian patients with ALS: a common founder and its geographical predilection. Neurobiol Aging 88: 156 e151&#x2013;156 e159. 10.1016/j.neurobiolaging.2019.12.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.12.024</ArticleId><ArticleId IdType="pubmed">32035847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelkar YD, Tyekucheva S, Chiaromonte F, Makova KD (2008) The genome-wide determinants of human and chimpanzee microsatellite evolution. Genome Res 18: 30&#x2013;38. 10.1101/gr.7113408</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.7113408</ArticleId><ArticleId IdType="pmc">PMC2134767</ArticleId><ArticleId IdType="pubmed">18032720</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JX, Helgason A, Masson G, Ebenesersdottir SS, Li H, et al.. (2012) A direct characterization of human mutation based on microsatellites. Nat Genet 44: 1161&#x2013;1165. 10.1038/ng.2398</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2398</ArticleId><ArticleId IdType="pmc">PMC3459271</ArticleId><ArticleId IdType="pubmed">22922873</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, Gascon E, Tran H, Chou HJ, Gendron TF, et al.. (2013) Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol 126: 385&#x2013;399. 10.1007/s00401-013-1149-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1149-y</ArticleId><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh E, Lee EB, Neal D, Wood EM, Toledo JB, et al.. (2015) Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathol 130: 363&#x2013;372. 10.1007/s00401-015-1445-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1445-9</ArticleId><ArticleId IdType="pmc">PMC4545720</ArticleId><ArticleId IdType="pubmed">26022924</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, Murray ME, Heckman MG, et al.. (2013) Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 12: 978&#x2013;988. 10.1016/S1474-4422(13)70210-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70210-2</ArticleId><ArticleId IdType="pmc">PMC3879782</ArticleId><ArticleId IdType="pubmed">24011653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruun GH, Doktor TK, Borch-Jensen J, Masuda A, Krainer AR, et al.. (2016) Global identification of hnRNP A1 binding sites for SSO-based splicing modulation. BMC Biol 14: 54. 10.1186/s12915-016-0279-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12915-016-0279-9</ArticleId><ArticleId IdType="pmc">PMC4932749</ArticleId><ArticleId IdType="pubmed">27380775</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairbrother WG, Yeh RF, Sharp PA, Burge CB (2002) Predictive identification of exonic splicing enhancers in human genes. Science 297: 1007&#x2013;1013. 10.1126/science.1073774</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1073774</ArticleId><ArticleId IdType="pubmed">12114529</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, et al.. (2016) Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron 90: 535&#x2013;550. 10.1016/j.neuron.2016.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, et al.. (2013) Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A 110: E4530&#x2013;4539. 10.1073/pnas.1318835110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SW, Taggart AJ, Heintzelman C, Cygan KJ, Hull CG, et al.. (2017) Widespread intra-dependencies in the removal of introns from human transcripts. Nucleic Acids Res 45: 9503&#x2013;9513. 10.1093/nar/gkx661</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx661</ArticleId><ArticleId IdType="pmc">PMC5766209</ArticleId><ArticleId IdType="pubmed">28934498</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, et al.. (2013) RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80: 415&#x2013;428. 10.1016/j.neuron.2013.10.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan G, Zhang Y, Gu Y, Kankel MW, Gao FB, et al.. (2020) CRISPR deletion of the C9ORF72 promoter in ALS/FTD patient motor neurons abolishes production of dipeptide repeat proteins and rescues neurodegeneration. Acta Neuropathol. 10.1007/s00401-020-02154-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02154-6</ArticleId><ArticleId IdType="pmc">PMC7300081</ArticleId><ArticleId IdType="pubmed">32266467</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang JY, Moccia R, Mordes DA, et al.. (2016) Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med 8: 347ra393. 10.1126/scitranslmed.aaf6038</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6038</ArticleId><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Zhou X, Robins AM, Paushter DH, Kim D, et al.. (2016) The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol Commun 4: 51. 10.1186/s40478-016-0324-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0324-5</ArticleId><ArticleId IdType="pmc">PMC4870812</ArticleId><ArticleId IdType="pubmed">27193190</ArticleId></ArticleIdList></Reference><Reference><Citation>Vourc&#x2019;h P, Wurmser F, Brulard C, Mouzat K, Kassem S, et al.. (2021) Genes containing hexanucleotide repeats resembling C9ORF72 and expressed in the central nervous system are frequent in the human genome. Neurobiol Aging 97: 148 e141&#x2013;148 e147. 10.1016/j.neurobiolaging.2020.07.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.07.027</ArticleId><ArticleId IdType="pubmed">32843153</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, et al.. (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol Ther 19: 2178&#x2013;2185. 10.1038/mt.2011.201</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2011.201</ArticleId><ArticleId IdType="pmc">PMC3242664</ArticleId><ArticleId IdType="pubmed">21971427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay C, Collins JA, Caron NS, Agostinho LA, Findlay-Black H, et al.. (2019) A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease. Am J Hum Genet 105: 1112&#x2013;1125. 10.1016/j.ajhg.2019.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2019.10.011</ArticleId><ArticleId IdType="pmc">PMC6904807</ArticleId><ArticleId IdType="pubmed">31708117</ArticleId></ArticleIdList></Reference><Reference><Citation>Skotte NH, Southwell AL, Ostergaard ME, Carroll JB, Warby SC, et al.. (2014) Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One 9: e107434. 10.1371/journal.pone.0107434</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0107434</ArticleId><ArticleId IdType="pmc">PMC4160241</ArticleId><ArticleId IdType="pubmed">25207939</ArticleId></ArticleIdList></Reference><Reference><Citation>Akimoto C, Volk AE, van Blitterswijk M, Van den Broeck M, Leblond CS, et al.. (2014) A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet 51: 419&#x2013;424. 10.1136/jmedgenet-2014-102360</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2014-102360</ArticleId><ArticleId IdType="pmc">PMC4033024</ArticleId><ArticleId IdType="pubmed">24706941</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>